The early mortality rate of people infected with coronavirus (COVID-2019) in Wuhan, China: Review of three retrospective studies.
Coronavirus
Wuhan
coronavirus disease
non-survivors
novel coronavirus pneumonia
Journal
Journal of pharmacy & bioallied sciences
ISSN: 0976-4879
Titre abrégé: J Pharm Bioallied Sci
Pays: India
ID NLM: 101537209
Informations de publication
Date de publication:
Historique:
received:
19
04
2020
revised:
29
04
2020
accepted:
12
06
2020
entrez:
26
10
2020
pubmed:
27
10
2020
medline:
27
10
2020
Statut:
ppublish
Résumé
The infection with coronavirus and non-survivor cases have been escalated since the first inception between January and March 2020. Therefore, reviewing the collated clinical characteristics of non-survivors might assist in current preventive efforts, triaging, and management of survivors. The aim of this review was to summarize the clinical characteristics of non-survivor cases due to the infection caused by a novel coronavirus and to identify the relevant data that might put the new cases at increased mortality. We have identified three published articles on novel coronavirus reported during December 01, 2020, to March 15, 2020, which have described the mortality rate in Wuhan, Hubei, China. The mean duration of studies (i.e., the three retrospective studies with 278 cases) was 24.7 days, and the duration of onset to dyspnea was variable between 8 and 5 days. The main reported complications were acute respiratory distress, pneumonia, acute kidney injury, and acute cardiac disease. The overall major comorbidity reported was cardiovascular diseases at 23.7% (66 of 278). The reported overall mortality rate was 8.3% (23 of 278), with the highest mortality rate of 15.0% (6 of 41) reported in Jin Yintan Hospital at Wuhan city. The clinical characteristics of the non-survivors from the novel coronavirus included adult males, aged older than 50 years, having comorbidities of cardiovascular disease, respiratory distress syndrome, acute kidney injury, and diabetes with higher admission to the intensive care unit. The mortality rate was high in two of the reported studies (15.0% and 11.0%), which was decreased in the later-dated study to 3.4%.
Sections du résumé
BACKGROUND
BACKGROUND
The infection with coronavirus and non-survivor cases have been escalated since the first inception between January and March 2020. Therefore, reviewing the collated clinical characteristics of non-survivors might assist in current preventive efforts, triaging, and management of survivors. The aim of this review was to summarize the clinical characteristics of non-survivor cases due to the infection caused by a novel coronavirus and to identify the relevant data that might put the new cases at increased mortality.
MATERIALS AND METHODS
METHODS
We have identified three published articles on novel coronavirus reported during December 01, 2020, to March 15, 2020, which have described the mortality rate in Wuhan, Hubei, China.
RESULTS
RESULTS
The mean duration of studies (i.e., the three retrospective studies with 278 cases) was 24.7 days, and the duration of onset to dyspnea was variable between 8 and 5 days. The main reported complications were acute respiratory distress, pneumonia, acute kidney injury, and acute cardiac disease. The overall major comorbidity reported was cardiovascular diseases at 23.7% (66 of 278). The reported overall mortality rate was 8.3% (23 of 278), with the highest mortality rate of 15.0% (6 of 41) reported in Jin Yintan Hospital at Wuhan city.
CONCLUSIONS
CONCLUSIONS
The clinical characteristics of the non-survivors from the novel coronavirus included adult males, aged older than 50 years, having comorbidities of cardiovascular disease, respiratory distress syndrome, acute kidney injury, and diabetes with higher admission to the intensive care unit. The mortality rate was high in two of the reported studies (15.0% and 11.0%), which was decreased in the later-dated study to 3.4%.
Identifiants
pubmed: 33100781
doi: 10.4103/jpbs.JPBS_282_20
pii: JPBS-12-223
pmc: PMC7574747
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
223-233Informations de copyright
© 2020 Journal of Pharmacy and Bioallied Sciences.
Déclaration de conflit d'intérêts
There are no conflicts of interest.
Références
Lancet. 2020 Feb 15;395(10223):514-523
pubmed: 31986261
Emerg Infect Dis. 2013 Jun;19(6):989-91
pubmed: 23739658
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
N Engl J Med. 2020 Feb 27;382(9):872-874
pubmed: 31991079
Int J Antimicrob Agents. 2020 Mar;55(3):105924
pubmed: 32081636
PLoS Pathog. 2017 Nov 30;13(11):e1006698
pubmed: 29190287
Nature. 2013 Nov 28;503(7477):535-8
pubmed: 24172901
Int J Infect Dis. 2020 May;94:128-132
pubmed: 32251805
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
Lancet Respir Med. 2020 May;8(5):475-481
pubmed: 32105632
Science. 2005 Oct 28;310(5748):676-9
pubmed: 16195424
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
N Engl J Med. 2020 Feb 20;382(8):692-694
pubmed: 31978293